Authors

Jeffrey S. Weber, MD, PhD, NYU Langone Medical Center

Jeffrey Weber, MD, PhD, NYU Langone Medical Center

Jeffrey Wolf, MD

Latest:

Dr. Wolf Discusses High-Risk Multiple Myeloma

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.

Jeffrey Zonder, MD

Latest:

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Jeffrey Zweig, MD

Latest:

The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?

With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.

Jena D. French, PhD

Latest:

Jena French on Combinations With Immunotherapy in Thyroid Cancer

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.

Jenna Bassett, PhD

Latest:

Novel Agents Aimed at Disrupting Cancer Metabolism Gain Ground

Since the Warburg effect has been observed in the majority of cancer types, many studies have focused on developing therapies that target metabolic pathways.

Jennie Crews, MD, MMM, FACP

Latest:

Dr. Crews Reflects on the Achievements of the ACCC During Her Presidency

The outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.

Jennifer A. Stein, MD, PhD

Latest:

Dr. Stein on Targeted Therapies for Melanoma

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.

Jennifer A. Woyach, MD

Latest:

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Jennifer Bellon, MD

Latest:

Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Jennifer Brown MD, PhD

Latest:

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Jennifer Brown, MD, PhD, Harvard Medical School

Jennifer Carlisle, MD

Latest:

Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC

Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.

Jennifer Chan, MD, MPH

Latest:

Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

Jennifer E. Amengual, MD

Latest:

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Jennifer Eads, MD

Latest:

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Jennifer Eads, MD, Case Western Reserve University

Jennifer K. Litton, MD

Latest:

Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Jennifer Kelly, MD, PhD

Latest:

Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer Patient

Oncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.